RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM DiseasePRNewsWire • 01/26/23
RedHill Announces Publication of Positive Phase 2 Study Results with Once-Daily Oral RHB-107 in Non-Hospitalized COVID-19PRNewsWire • 01/03/23
Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for RedHill Biopharma Ltd. (NASDAQ:RDHL)Accesswire • 12/07/22
RedHill Biopharma Announces Positive New Data with Opaganib for Nuclear Radiation InjuryPRNewsWire • 11/17/22
RedHill Accelerates Opaganib's Nuclear Radiation Protection Program - Positive Data PublishedPRNewsWire • 11/14/22
RedHill Biopharma Reaches Agreement in Principle with HCR to Extinguish All Debt Obligations in Exchange for Movantik®PRNewsWire • 11/14/22
RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment PatentPRNewsWire • 10/19/22
RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5PRNewsWire • 10/03/22
RedHill Biopharma Announces EU Orphan Drug Designation for RHB-204 for NTM InfectionsPRNewsWire • 08/17/22
RedHill Announces New H. pylori and COVID-19 Data Publication and Presentations at Leading Upcoming Scientific ConferencesPRNewsWire • 07/12/22